120 related articles for article (PubMed ID: 34879868)
1. Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert's and patient's perspective.
Jonaitis L; Marković S; Farkas K; Gheorghe L; Krznarić Ž; Salupere R; Mokricka V; Spassova Z; Gatev D; Grosu I; Lijović A; Mitrović O; Saje M; Schafer E; Uršič V; Roblek T; Drobne D
BMC Proc; 2021 Dec; 15(Suppl 17):25. PubMed ID: 34879868
[TBL] [Abstract][Full Text] [Related]
2. The global burden of IBD: from 2015 to 2025.
Kaplan GG
Nat Rev Gastroenterol Hepatol; 2015 Dec; 12(12):720-7. PubMed ID: 26323879
[TBL] [Abstract][Full Text] [Related]
3. Quality of life related to oral, subcutaneous, and intravenous biologic treatment of inflammatory bowel disease: a time trade-off study.
Holko P; Kawalec P; Mossakowska M
Eur J Gastroenterol Hepatol; 2018 Feb; 30(2):174-180. PubMed ID: 29194233
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities.
Bittner B; Richter W; Schmidt J
BioDrugs; 2018 Oct; 32(5):425-440. PubMed ID: 30043229
[TBL] [Abstract][Full Text] [Related]
5. Perspectives of health care use and access to care for individuals living with inflammatory bowel disease in rural Canada.
Rohatinsky N; Boyd I; Dickson A; Fowler S; Peña-Sánchez JN; Quintin CL; Risling T; Russell B; Wicks K; Wicks M
Rural Remote Health; 2021 Apr; 21(2):6358. PubMed ID: 33820422
[TBL] [Abstract][Full Text] [Related]
6. The non-drug costs associated with the administration of an intravenous biologic treatment in the hospital setting.
Cronin J; Moore S; Lenihan N; O'Shea M; Woods N
Ir J Med Sci; 2019 Aug; 188(3):821-834. PubMed ID: 30467804
[TBL] [Abstract][Full Text] [Related]
7. Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial.
Atreja A; Khan S; Rogers JD; Otobo E; Patel NP; Ullman T; Colombel JF; Moore S; Sands BE;
JMIR Res Protoc; 2015 Feb; 4(1):e23. PubMed ID: 25693610
[TBL] [Abstract][Full Text] [Related]
8. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
9. How do patients with inflammatory bowel disease want their biological therapy administered?
Allen PB; Lindsay H; Tham TC
BMC Gastroenterol; 2010 Jan; 10():1. PubMed ID: 20064220
[TBL] [Abstract][Full Text] [Related]
10. Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients.
Cha JM; Park DI; Park SH; Shin JE; Kim WS; Yang SK
J Korean Med Sci; 2017 Jan; 32(1):85-94. PubMed ID: 27914136
[TBL] [Abstract][Full Text] [Related]
11. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease.
Jolles S; Orange JS; Gardulf A; Stein MR; Shapiro R; Borte M; Berger M
Clin Exp Immunol; 2015 Feb; 179(2):146-60. PubMed ID: 25384609
[TBL] [Abstract][Full Text] [Related]
12. Promoting and supporting self-management for adults living in the community with physical chronic illness: A systematic review of the effectiveness and meaningfulness of the patient-practitioner encounter.
Rees S; Williams A
JBI Libr Syst Rev; 2009; 7(13):492-582. PubMed ID: 27819974
[TBL] [Abstract][Full Text] [Related]
13. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR
World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395
[TBL] [Abstract][Full Text] [Related]
14. The patient experience of patient-centered communication with nurses in the hospital setting: a qualitative systematic review protocol.
Newell S; Jordan Z
JBI Database System Rev Implement Rep; 2015 Jan; 13(1):76-87. PubMed ID: 26447009
[TBL] [Abstract][Full Text] [Related]
15. Critical Care Network in the State of Qatar.
Hijjeh M; Al Shaikh L; Alinier G; Selwood D; Malmstrom F; Hassan IF
Qatar Med J; 2019; 2019(2):2. PubMed ID: 31763205
[TBL] [Abstract][Full Text] [Related]
16. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Pollock RF; Muduma G
Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
[TBL] [Abstract][Full Text] [Related]
17. Perception of the impact of intravenous biological treatment on the work and professional environment in patients with inflammatory bowel disease.
González-Muñoza C; Gely C; Gordillo J; Calafat M; Bertoletti F; Cañete F; Mañosa M; López-Faba A; Torres P; Domènech E; Garcia-Planella E
Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38723767
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
